Codexis, Inc (NASDAQ: CDXS) was up 28% this morning in premarket trading. Still holding onto gains of roughly 12%, let’s explore the driving force behind the racking backing of the protein engineering company.
With pharmaceutical companies like Merck and Zomedica welcoming strong gains last week following various pieces of promising news; Codexis is the latest to please its eager investors – for a few reasons…
Firstly, the Codexis stock price is still rising in the trials of its agreement with Merck last month for the licensing and supplying of an enzyme used to manufacture sitagliptin – a key ingredient in popular diabetes medication. Whilst we saw a 13% drop off last week, Codexis appears to be bouncing back stronger than ever.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
The deal with Merck is arguably not the only factor at play here. Codexis stock has received further backing from a variety of investment analysts; particularly Craig Hallum, who confirmed a “buy” rating for the stock on Friday, with an overall price target of $30. Codexis’ “buy” rating has been reiterated by a number of prominent research analysts, suggesting price targets indicative of long-term growth.
The Codexis stock price is currently sitting just over the $26 mark, and with arguments for the stock’s upside potential and fundamental growth within the company, it isn’t much of a surprise that Codexis is on the rise again.
Should You Invest in Codexis Shares?
One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It’s a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now
